SLC35A2 Inhibitors
Chemical inhibitors of SLC35A2 can exert their influence by disrupting various stages of the glycosylation process, in which this protein is a key participant. Tunicamycin indirectly inhibits SLC35A2 by targeting the initial step in glycoprotein biosynthesis. By halting the transfer of N-acetylglucosamine-1-phosphate to dolichol phosphate, it creates a bottleneck that indirectly impedes the function of SLC35A2, since subsequent glycosylation steps cannot proceed without this initial event. Additionally, the chemical Castanospermine and the related compound Deoxynojirimycin inhibit glucosidases, enzymes that are critical for the proper trimming of glycoproteins. Their inhibition results in the improper processing of glycoproteins, which indirectly impedes the glycosylation process SLC35A2 is involved in.
Similarly, Swainsonine and Kifunensine inhibit mannosidase II and I, respectively, leading to the build-up of improper glycans and indirectly hampering the role of SLC35A2 in the maturation of glycoproteins. The compound 1-Deoxymannojirimycin follows a similar mechanism, causing an accumulation of incorrectly processed glycoproteins and indirectly affecting SLC35A2 function. On a different pathway, NB-DNJ (Miglustat) inhibits glucosylceramide synthase, which could lead to disturbances in the glycolipid composition and potentially impede the optimal conditions required for SLC35A2 function. Fumonisin B1 targets ceramide synthase, leading to alterations in membrane lipid compositions that could disrupt the lipid environment essential for the proper functioning of SLC35A2. Bafilomycin A1, a V-ATPase inhibitor, disrupts organelle acidification, such as in the Golgi, where SLC35A2 is active, which could indirectly inhibit SLC35A2 by changing the pH gradient required for its activity. Monensin, an ionophore, disrupts intracellular ion gradients, which can indirectly inhibit SLC35A2 by affecting the ion homeostasis that is necessary for its transport function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits SLC35A2 by blocking the first step in glycoprotein biosynthesis, which is the transfer of N-acetylglucosamine-1-phosphate to dolichol phosphate. This action indirectly inhibits the protein's function since proper glycosylation is not initiated. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
Castanospermine inhibits glucosidases, enzymes that are essential for the proper trimming of glycoproteins. By inhibiting these enzymes, the glycoproteins may not be processed correctly, indirectly inhibiting the function of SLC35A2 in glycosylation. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $72.00 $142.00 | ||
Similar to castanospermine, deoxynojirimycin inhibits glucosidase enzymes. The improper glycoprotein processing as a result of glucosidase inhibition indirectly affects SLC35A2's role in the glycosylation pathway. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
Swainsonine inhibits mannosidase II, an enzyme involved in the processing of N-linked glycans. This impedes the maturation of glycoproteins, thereby indirectly inhibiting SLC35A2's function in glycosylation. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $132.00 $529.00 $1005.00 $6125.00 | 25 | |
Kifunensine inhibits mannosidase I, leading to the accumulation of high-mannose glycans, which indirectly disrupts the glycosylation process that SLC35A2 is involved in. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
As an inhibitor of mannosidase I, 1-Deoxymannojirimycin causes an accumulation of improperly processed glycoproteins, thereby indirectly inhibiting SLC35A2's function in glycoprotein synthesis. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $117.00 $469.00 | 18 | |
Fumonisin B1 inhibits ceramide synthase, which could alter the lipid composition of membranes and indirectly affect the function of SLC35A2 by disrupting the lipid environment necessary for its proper function. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the V-ATPase proton pump, disrupting acidification of organelles like the Golgi, where SLC35A2 operates. This disruption can indirectly inhibit the function of SLC35A2 by altering the organelle pH which is crucial for its activity. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin acts as an ionophore that disrupts intracellular ion gradients, particularly in compartments of the secretory pathway, which can indirectly inhibit SLC35A2 by disturbing the ion homeostasis required for its transport function. | ||||||